Science 37, Synlogic partner on study for investigational drug phenylketonuria

Science 37 Holdings (SNCE) has been chosen by Synlogic, (SYBX). Synlogic chose Science 37 to provide virtual clinical trial technology and services for Synpheny-3, its ongoing pivotal, Phase III trial of investigational drug labafenogene marselecobac as a potential treatment for phenylketonuria, a rare, genetic metabolic disorder. The Synpheny-3 trial aims to study the effectiveness of labafenogene marselecobac, an orally administered, investigational medicine based on a genetically engineered probiotic, in PKU patients. Synlogic anticipates enrolling approximately 150 patients who have the potential to receive the investigational drug and to be monitored for up to three years. The Science 37 Metasite will expand access to the trial for patients who may be unable or prefer not to travel to research sites for study visits. Science 37 will also provide its unified platform to the study’s physical research sites, ensuring end-to-end data quality and consistency, no matter where or how data is captured.